New hope for Hard-to-Treat cancers: experimental drug QLS1317 enters human trials
NCT ID NCT07552376
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called QLS1317 in 120 people with advanced solid tumors that have high microsatellite instability (MSI-H) or deficient DNA mismatch repair (dMMR). These patients have already tried standard treatments without success. The study aims to find a safe dose and see if the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QLS1317
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific genetic features (MSI-H/dMMR) and have not responded to other therapies.
What could go wrong
This is an early Phase 1 trial with only 120 participants, so it is primarily testing safety and dosing. The drug may not prove effective, and side effects are unknown at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H OR DMMR ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••